Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

101. Systematic review and meta-analysis on the risk of oesophageal adenocarcinoma and high grade dysplasia in adult GERD patients treated or not treated with proton pump inhibitors

Systematic review and meta-analysis on the risk of oesophageal adenocarcinoma and high grade dysplasia in adult GERD patients treated or not treated with proton pump inhibitors Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

102. Proton pump inhibitor therapy and risk of osteoporosis and fracture: a systematic review and meta-analysis

Proton pump inhibitor therapy and risk of osteoporosis and fracture: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

103. Proton pump inhibitor use and the risk of acute kidney injury: a systematic review

Proton pump inhibitor use and the risk of acute kidney injury: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

104. Are We Overusing Proton Pump Inhibitors?

Are We Overusing Proton Pump Inhibitors? Are We Overusing Proton Pump Inhibitors? – Clinical Correlations Search Are We Overusing Proton Pump Inhibitors? November 13, 2015 7 min read [1]. PPIs are the most potent inhibitors of gastric secretion and are used to treat common upper gastrointestinal disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. The effectiveness of PPIs and their perceived low toxicity profile have led to their popularity and even inappropriate (...) , Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-319. 7. U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Published March 2, 2011. Accessed 8. Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4):553-556. 9. Khalili H, Huang ES, Jacobson

2015 Clinical Correlations

105. [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors]

[Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors] Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons [Notice of the impact of the decrease of the maximum payable amount (...) for the class of proton pump inhibitors] Jehanno C, Robitaille J, Bouchard S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jehanno C, Robitaille J, Bouchard S. Avis sur l'impact de la baisse du prix maximal payable sur la classe des inhibiteurs de la pompe à protons. [Notice of the impact of the decrease of the maximum payable amount for the class

2015 Health Technology Assessment (HTA) Database.

106. Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus Proton pump inhibitors (PPIs) are associated with very infrequent cases of subacute cutaneous lupus erythematosus (SCLE), a non-scarring dermatosis that can develop in sun-exposed areas (...) . Published 8 September 2015 From: Therapeutic area: , Contents If a patient treated with a proton pump inhibitor ( Proton pump inhibitors A review of medical records of patients at a dermatology unit in a university hospital in Denmark identified 19 cases of A further 17 cases of Cumulatively, of the cases reviewed from literature and from case reports submitted by Sandholdt LH and others. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2014; 170: 342–51. Almebayadh M

2015 MHRA Drug Safety Update

107. Proton Pump Inhibitors for Gastrointestinal Conditions

Proton Pump Inhibitors for Gastrointestinal Conditions Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Proton Pump Inhibitors for Gastrointestinal Conditions: A Review

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

108. Proton Pump Inhibitors in Upper GI Bleeds

Proton Pump Inhibitors in Upper GI Bleeds Emergency Medicine > Journal Club > Archive > August 2015 Toggle navigation August 2015 Proton Pump Inhibitors in Upper GI Bleeds Vignette You're working a shift in EM-­‐2 one day when you pick up a patient with the chief\ complaint of "bloody emesis." The patient is a 45 year old male with a history of chronic low back pain who takes daily naproxen (250 mg BID). His pain worsened two months ago when he was in an MVC, and he has been taking ibuprofen (...) PT/INR and PTT are normal. An NG tube is placed and returns coffee grounds with streaks of blood that do not clear after lavage with one liter of normal saline. You order a type and screen and cross him for 4 units (just incase). You call the GI fellow, thinking that the patient probably needs an upper endoscopy. The GI fellow asks that you start the patient on a continuous infusion of intravenous antoprazole. You wonder how useful IV proton pump inhibitors actually are in the setting of upper GI

2015 Washington University Emergency Medicine Journal Club

109. Proton pump inhibitors versus H2 receptor antagonists in prevention of upper gastrointestinal events associated with aspirin plus clopidogrel

Proton pump inhibitors versus H2 receptor antagonists in prevention of upper gastrointestinal events associated with aspirin plus clopidogrel Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

110. Proton pump inhibitors for functional dyspepsia [Cochrane Protocol]

Proton pump inhibitors for functional dyspepsia [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2015 PROSPERO

111. Proton pump inhibitor-based triple therapies versus dual therapies for Helicobacter pylori eradication [Cochrane Protocol]

Proton pump inhibitor-based triple therapies versus dual therapies for Helicobacter pylori eradication [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

112. Efficacy of vonoprazan compared to proton pump inhibitors for patients with gastroesophageal reflux disease (GERD) in Japan: a network meta-analysis

Efficacy of vonoprazan compared to proton pump inhibitors for patients with gastroesophageal reflux disease (GERD) in Japan: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

113. Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up

Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP) [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C. Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP). [Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). 2014 Authors

2014 Health Technology Assessment (HTA) Database.

114. Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis

Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients: A Systematic Review and Meta-Analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2014 PedsCCM Evidence-Based Journal Club

115. Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost

Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost – Clinical Correlations Search Proton Pump Inhibitors: Acid Suppression with a Nutritional Cost June 13, 2014 5 min read By Dana Zalkin Peer Reviewed In the late 1970s evidence began to emerge that a newly discovered pump, [1]. With this discovery, further research [2]. We now have drugs that do just that: the proton pump inhibitors (PPIs). Proton pump inhibitors (...) Nutr. 1997;66(4):750-759. 7. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999;19:357-377. 8. Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9(3):162-167. doi: 10.1016/j.jamda.2007.10.004. 9. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol

2014 Clinical Correlations

116. Proton Pump Inhibitors and Clostridium Difficile Infection

Proton Pump Inhibitors and Clostridium Difficile Infection Proton Pump Inhibitors and Clostridium Difficile Infection – Clinical Correlations Search Proton Pump Inhibitors and Clostridium Difficile Infection March 20, 2014 4 min read By Aaron Smith, MD Peer Reviewed First introduced in the late 1980s, proton pump inhibitors (PPIs) have revolutionized the treatment of gastric acid-related disorders and have been described as a miracle drug by patients and physicians alike. As is often the case (...) al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336(8707):97–100. [3] [4] Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology. 1982;83(2):465-469. [5] Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile

2014 Clinical Correlations

117. Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit Full Text available with Trip Pro

Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit IMPORTANCE Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile (...) %; P < .001) occurred less frequently in the H2RA group. After adjusting for propensity score and covariates, odds ratios of GI hemorrhage (2.24; 95% CI, 1.81-2.76), pneumonia (1.2; 95% CI, 1.03-1.41), and CDI (1.29; 95% CI, 1.04-1.64) were greater with PPIs. Similar results were obtained in the propensity-matched models of 8799 patients in each cohort. CONCLUSIONS AND RELEVANCE Proton pump inhibitors are associated with greater risks of GI hemorrhage, pneumonia, and CDI than H2RAs

2014 EvidenceUpdates

118. [Notice on the reimbursement of proton pump inhibitors]

[Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Avis sur le remboursement des inhibiteurs de la pompe à protons [Notice on the reimbursement of proton pump inhibitors] Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Avis sur le remboursement des inhibiteurs de la pompe à protons . [Notice on the reimbursement of proton pump inhibitors] Quebec: Institut national d'excellence en sante et en services sociaux (INESSS). ETMIS; 9(2). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Proton Pump Inhibitors Language Published French Country of organisation Canada Province or state Quebec English summary An English language summary is available. Address for correspondence

2014 Health Technology Assessment (HTA) Database.

119. Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up

Randomised controlled trial: For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5?years of follow-up For proton pump inhibitor-dependent gastro-oesophageal reflux, laparoscopic fundoplication is superior to medical therapy at 5 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For proton pump inhibitor-dependent gastro-oesophageal reflux

2014 Evidence-Based Medicine

120. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Full Text available with Trip Pro

Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs) suppress the production of gastric acid and thus may lead to malabsorption of vitamin B12. However, few data exist regarding the associations between long-term exposure to these medications and vitamin B12 deficiency in large population-based studies.To study the association between use of PPIs and H2RAs and vitamin B12 deficiency (...) less than 0.75 pills/d (OR, 1.63 [95% CI, 1.48-1.78]; P = .007 for interaction).Previous and current gastric acid inhibitor use was significantly associated with the presence of vitamin B12 deficiency. These findings should be considered when balancing the risks and benefits of using these medications.

2013 JAMA